NCT03301350 Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer Status COMPLETED Phase PHASE2
NCT03300843 Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer Status TERMINATED Phase PHASE2
NCT03296683 Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer Status UNKNOWN Phase NA
NCT03295916 Stereotactic Body Radiotherapy for Patients With Breast Cancer Oligometastasis Status UNKNOWN Phase EARLY_PHASE1
NCT03295695 PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient Status WITHDRAWN Phase EARLY_PHASE1
NCT03294330 SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer Status COMPLETED Phase PHASE3
NCT03292536 Merestinib on Bone Metastases in Subjects With Breast Cancer Status TERMINATED Phase PHASE1
NCT03289364 Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients Status COMPLETED Phase NA
NCT03289286 Pilot Study Evaluating a Perioperative E-follow-up Protocol in Patients With Ambulatory Surgery for Breast Cancer Status COMPLETED Phase NA
NCT03289195 Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer Status ACTIVE_NOT_RECRUITING Phase NA
NCT03289039 Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer Status TERMINATED Phase PHASE2
NCT03288792 A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts Status TERMINATED Phase NA
NCT03286257 Can Exercise Training Reduce the Frequency and Severity of Hot Flushes Associated With Breast Cancer Treatment? Status COMPLETED Phase NA
NCT03285607 MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer Status WITHDRAWN Phase PHASE1
NCT03285412 CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03284957 Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer Status TERMINATED Phase PHASE1/PHASE2